Transitional Drugs 5 for NHS Wales goes to Janssen, Mercury and Teva
- NHS Wales Shared Services Partnership
- Wales
- Open, 9 bids
- 1 January 2026 to 31 December 2027
NHS Wales Shared Services Partnership bought three medicines that have recently lost exclusivity from Janssen, Mercury Pharmaceuticals and Teva UK Limited. The award came to £5.6m, about an eighth of the £45.1m estimate.
The medicines are aflibercept, dapagliflozin and golimumab. Denosumab was named at the planning stage but left out of the tender. Products had to pass a quality check. Cost then counted for 85% of the score and environmental and social value for 15%.
Nine bids came in to the open tender. The three suppliers were chosen in November 2025, with no split of the value between them. The contract can run to December 2028 with its extension.
Contract ends December 2027
- What
- Medicines supply
- Supplier
- 3 suppliers
- Janssen and 2 more
- Value
- £5.58m
- How it was bought
- Open
- 9 bids
- Dates and next
- Jan 2026 to Dec 2027
- Being re-tendered now